# Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

> **NCT03436394** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 31 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Evobrutinib

## Key facts

- **NCT ID:** NCT03436394
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-02-22
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436394, "Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03436394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*